GlassScriptPhysician profile
Miranda Martin
NPI 1942907498
$8,074.84
in general payments reported to CMS, 2019-2025
45 companies · $2,790 in 2025
The $2,790 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,352 · 2024: $2,933 · 2025: $2,790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,911 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,911.09 |
| Education | $163.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,757.92 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $519.95 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Genentech USA, INC. | $440.59 | 2024-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Pfizer INC. | $401.80 | 2023-2025 | |
| Lundbeck LLC | $372.55 | 2023-2025 | Vyepti, Rexulti |
| Ucb, INC. | $312.19 | 2023-2025 | Fintepla, Rystiggo, Briviact |
| Lilly USA, LLC | $304.56 | 2023-2025 | Amyvid, Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $295.53 | 2023-2025 | |
| Biogen, INC. | $290.19 | 2023-2025 | Vumerity, Tysabri, Skyclarys |
| Sumitomo Pharma America, INC. | $259.42 | 2023-2024 | Aptiom |
| Emd Serono, INC. | $250.15 | 2023-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $212.55 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $193.45 | 2023-2025 | Ingrezza, Ongentys |
| Celgene Corporation | $182.26 | 2024-2025 | Zeposia |
| Kyowa Kirin, INC. | $177.78 | 2023-2024 | Nourianz |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $176.51 | 2023 | Adlarity |
| Janssen Biotech, INC. | $169.43 | 2025 | |
| Genzyme Corporation | $128.96 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $125.61 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $117.88 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Axsome Therapeutics, INC. | $111.19 | 2025 | Symbravo |
| Sk Life Science, INC. | $88.92 | 2023-2025 | |
| Azurity Pharmaceuticals, INC. | $87.44 | 2023-2025 | Horizant, Horizant |
| Tanabe Pharma America, INC. | $87.15 | 2023-2024 | |
| Scilex Pharmaceuticals INC. | $84.52 | 2023-2025 | Ztlido |
| Grifols USA, LLC | $83.71 | 2023-2024 | Gamunex-C |
| Ipsen Biopharmaceuticals, INC | $81.97 | 2023 | Dysport |
| Tg Therapeutics, INC. | $79.65 | 2023-2025 | |
| Ge Healthcare | $66.58 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $66.41 | 2025 | Crexont |
| Sandoz INC. | $61.06 | 2023-2024 | |
| Livanova USA, INC. | $58.39 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Alnylam Pharmaceuticals INC. | $54.32 | 2023 | Onpattro |
| Acadia Pharmaceuticals INC | $51.45 | 2025 | Nuplazid, Daybue |
| Neurelis, INC. | $49.80 | 2023-2024 | Valtoco |
| Octapharma USA, INC. | $47.90 | 2023 | Octagam Immune Globulin (Human) |
| Avion Pharmaceuticals | $42.45 | 2023 | Dhivy |
| Jazz Pharmaceuticals INC. | $32.95 | 2023 | Epidiolex |
| Averitas Pharma INC. | $23.76 | 2024 | Qutenza |
| Amgen INC. | $23.31 | 2025 | Uplizna |
| Banner Life Sciences, LLC | $23.22 | 2023 | |
| Harmony Biosciences LLC | $21.88 | 2023 | Wakix |
| Alexion Pharmaceuticals, INC. | $21.61 | 2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $19.01 | 2024 | Hyqvia |
| Tonix Medicines, INC. | $16.91 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.